The Latest Breaking News from DHR

Although Danaher has underperformed the S&P 500 Index over the past year, analysts remain bullish about the stock’s prospects.

Healthcare giant Danaher has significantly underperformed the broader market over the past year, yet analysts remain strongly bullish on the stock’s longer-term prospects.

With Danaher gearing up to release its third-quarter earnings later this month, analysts expect double-digit earnings decline.

Danaher recently underperformed the healthcare sector, but Wall Street analysts are moderately bullish about the stock’s prospects.

Danaher is expected to release its second-quarter earnings later this month, and analysts project a double-digit bottom-line dip.

The healthcare industry is poised for tremendous growth driven by the aging population and rising incidence of chronic diseases. Hence, quality healthcare stocks, Danaher (DHR), Amgen (AMGN), and DexCom (DXCM), benefiting from an aging population, might be worth looking into. Read more….

Indian medical institutions aim to improve research quality and global rankings, focusing on impactful solutions for citizens' problems.

In the specialized field of spinoff companies, Veralto emerges as a prime investment opportunity, stemming from its recent spinoff from Danaher Corporation.

With rapidly increasing healthcare demands, numerous technological breakthroughs, and advanced research and development, the medical industry is well-poised for remarkable growth and profitability. As medical companies Danaher (DHR) and Stryker (SYK) gear to report their fourth-quarter earnings tomorrow, let’s determine if these stocks are ideal buys ahead of earnings….